A review of NT-proBNP studies in dogs by Perez and colleagues [153] yielded similar conclusions about the reliability of NT-proBNP as a general biomarker for canine DCM, while pointing out its weakness in early, preclinical stages of the disease. This evidence concerns the gene NPPB and familial dilated cardiomyopathy.